Special Investor Opportunity Report:
The Covid-19 Crisis is one of the biggest public health threats in a generation.
That’s why …
Edoceo is seeking funding to Fast-track Development of a Testing Platform Called V-Detect…
A SARS-CoV-2 Virus test designed to be:
Portable, for use almost anywhere
Quick, with results in under 30 minutes
Affordable, tests made available to all
Accurate, greatly reducing false results
Watch this video now for the details …
Watch this video to discover why Edoceo Devices is a great opportunity for investors as it pioneers point-of-need testing devices for the COVID-19 disease and eventually viruses causing diseases like HIV, dengue fever, influenza, Zika, and Hepatitis C, plus domestic animal viruses, 160 bacterial pathogens, and superbugs!
V-Detect is Expected to …
- Deliver accurate COVID-19 tests results based on RNA amplification similar to the current gold standard of testing.
- Eventually be expanded beyond SARS-CoV-2 testing capabilities to include detection of those viruses that cause HIV, hepatitis C, dengue fever, and even annual global flu outbreaks.
Read on for the 7 UNEXPECTED REASONS why investors could benefit from this disruptive tech.
But first, Edoceo is also developing a second, equally remarkable device called …
B-Detect, which is designed to …
- Be the fastest, easy-to-use, cost effective, portable device that detects the presence of 160 kinds of bacteria when in a virulent (harmful) state. This could help identify superbugs that experts expect could cost the global economy $100 trillion in healthcare, lost productivity, and lost lives over the next 30 years. 
- Eventually gain a foothold in multiple industries, with its first point of entry being shrimp farms, where bacterial invasions routinely cause massive crop and financial losses.
- Blood pressure monitoring devices, a market projected to reach $2.47 billion by 2026.
- Sleep apnea devices, with a market size projected to be a $12.61 billion market in the next four years.
- Blood glucose meters, with a projected global market size reaching $15.4 billion by 2026 
Reason #1: Technological Disruptors Have the Potential to Change the World & Boost Investor Returns
- Determine the existence of a viral or harmful bacterial infection so that treatment can begin quickly.
- Track the progress of treatment of bacterial infections to ensure antibiotics aren’t discontinued prematurely (something that plays a major role in the creation of superbugs).
- After detection of a bacterial infection and an antibiotic prescription, a quick test a few hours after medication has started can determine if the antibiotic is having an effect. If it isn’t, another antibiotic can be prescribed. This limits the ingestion of needless antibiotics, which is not only costly but can also build up the bacteria’s resistance.
- Prevent the evolution of new, even deadlier superbugs.
- Slow the spread of viruses.
Reason #2: V-Detect and B-Detect Could One Day Become Common Household Medical Devices, Offering Accessible Testing to Millions
- 3,384 aquaculture farms, where an undetected bacterial infection results in the loss of an entire pond, costing the farmers millions in lost stock and revenue …
- 113,394 veterinarians who keep millions of traditional and exotic pets (which are particularly susceptible to bacterial infection) healthy …
- More than 913,246 total cattle and calf operations, where bacterial invasion could have a negative impact not only to the farm and animals, but all the ancillary businesses and consumers who rely on dairy or meat …
- About 101,000 sheep operations …
- 13,572 pet stores …
- At least 486,400 primary care physicians and 6,146 hospitals available to treat people suffering from food poisoning, urinary tract infection and other dangerous bacterial outbreaks…
- And about 36,486 food processing plants, where even the smallest bacterial outbreak has devastating consequences
- 5 minute turnaround in the case of bacterial detection, and
- less than 30 minute test results for the virus causing COVID-19 and other dangerous viruses, too
Reason #3: The Bacterial Threat is Bigger Than You Know
Reason #4: Cutting Short the Debilitating Urinary Tract Infections that impact millions of people and cost the healthcare system billions
- An estimated 10.5 million doctors’ visits every year are for urinary tract infection (UTI) symptoms in the U.S.
- The societal costs of these UTI infections are about $3.5 billion per year.
- Current testing is slow, with patients — many of them elderly — often waiting up to three days for results as their condition may deteriorate. Worse, a side effect of UTIs in the elderly could be confusion, to add to the discomfort they’re experiencing.
- Over half of all women and one-quarter of men will have a UTI in their lifetime.
- Unchecked, UTI’s can lead to kidney infection, which can lead to sepsis. 
Reason #5: There’s A Way To Help Shrimp Farmers Save Billions Of Dollars A Year: Use B-Detect
Aquaculture, or fish farming, is a $243.5 billion industry. In fact, about half of all the fish consumed throughout the world are raised in giant, man-made ponds or tanks on dry land rather than caught in the wild.
There are about 3,000 fish farms in the U.S. Reliable statistics for other countries aren’t easy to get, but our research suggests there are at least 50,000 aquaculture installations worldwide, with a high percentage in Asia and Latin/South America. This is a huge – and hugely important – industry. But it has a $6 billion problem …
Fish can become infected, just like people and pets. And when fish are raised in confined environments, as they are in aquaculture installations, infection can spread like wildfire, wiping out an entire pond in less than a day.
The numbers are staggering. The aquaculture industry loses an estimated $6 billion a year because of diseased fish. In some years, approximately 40% of shrimp production is lost to disease.[iv]
So, it’s crucially important to identify an infection as quickly as possible.
With current testing technology, it takes days for aquaculture operators to identify infection-causing bacteria, by which time a significant percentage of their crop might already be sick or dying.
But Edoceo is designing B-Detect to signal onsite the presence of bacteria in shrimp within minutes, allowing treatment to begin immediately. And it could allow aquaculture operators to continuously monitor their ponds to ensure treatment is working as intended.
Reason #6: B-Detect Could Be the Answer to Help Food Processors Detect and Prevent Expensive and Deadly Bacterial Outbreaks
Reason #7: The Science Teams Behind V-Detect and B-Detect are Renowned for Their Technological Innovations
Ms. Tsai is the former Founder and CEO of HealthExpo, the largest consumer healthcare event in the U.S., where she grew the enterprise from concept to execution, attracting more than 50 million consumers. Before that, she was a General Partner in MassTech Ventures, a multi-million-dollar equity fund focused on technology development at Massachusetts Institute of Technology. She currently serves on the Board of Selectors for the Jefferson Foundation Awards and is on the board of the Prix Galien Foundation. In 1999, the Harvard Business School Alumni Chapter in New York recognized her with an Early Stage Honor Roll Award for Entrepreneurship.
Request Your Free, No-Obligation Edoceo Special Report Today!
 Flores-Mireles et al., 2015
Quara Devices Inc. (dba Edoceo Devices) Campaign
IMPORTANT NOTICE AND DISCLAIMER: All investments are subject to risk, which must be considered on an individual basis before making any investment decision. This is a paid advertisement to bring market awareness to Quara Devices Inc. (dba Edoceo Devices), its products and services, and a related private equity investment opportunity under Regulation A+ of the JOBS Act. Quara Devices Inc. (dba Edoceo Devices) hired Creative Direct Marketing Group, Inc (CDMG), an advertising agency, with a total budget of $150,000 to cover the costs associated with creating, printing media and distribution of this advertisement. . A related entity of the owners and management of CDMG purchased 300,000 shares of Quara Devices Inc. (dba Edoceo Devices) common stock on August 19, 2019 at a price of $0.05 per share after learning about its technology. Neither CDMG nor the related entity or any other affiliated individual or entity has any present intention to buy or sell any shares of Quara Devices Inc. (dba Edoceo Devices) now or in the near future and will not do so for a period of at least ninety (90) days following the date CDMG’s marketing efforts have ceased. This advertisement is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this advertisement, Edoceo or advertising agency’s copywriter purport to provide a complete analysis of any company or its financial position. CDMG is not, and does not purport to be, a broker-dealer or registered investment adviser. This advertisement is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC and/or other government filings. Investing in securities, particularly illiquid securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This advertisement contains forward-looking statements, including statements regarding Edoceo’s expected continual growth. Quara Devices Inc. (dba Edoceo Devices) notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the company’s actual results of operations. Factors that could cause actual results to differ include the size and growth of the market for the company’s products and/or services, the company’s ability to fund its capital requirements in the near term and long term, pricing pressures, etc. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of this advertisement is made or implied. Neither Quara Devices Inc. (dba Edoceo Devices) nor CDMG is affiliated, connected, or associated with, and are not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made to any rights in any third-party trademarks.